EDEN PRAIRIE, Minn., Jan. 24, 2019 (GLOBE NEWSWIRE) — In a release issued this morning by CHF Solutions, we have been advised by the company that the headline should read “Cardiothoracic Surgeon Daniel Beckles” rather than “Cardiologist Daniel Beckles” as originally issued. The corrected release follows:
CHF Solutions Sponsors Breakfast Symposium on Ultrafiltration Featuring Renowned Cardiothoracic Surgeon Daniel Beckles, M.D., Ph.D., at Society of Thoracic Surgeons 55th Annual Meeting
CHF Solutions (Nasdaq: CHFS), today announced it will be sponsoring a breakfast symposium at the Society of Thoracic Surgeons Annual Meeting, featuring Daniel Beckles, M.D., Ph.D., on Monday, January 28, 2019, at the Marriott Marquis in San Diego, California.
The symposium, titled, “A simplified approach to ultrafiltration in the management of fluid overloaded cardiac surgery patients,” will include discussion on the use of the Aquadex FlexFlow® system to help manage the risks associated with fluid overload in adult cardiac surgery. In addition, the company will be exhibiting at the meeting in Booth #1100, Hall G-F during the conference, which is held from January 27-29.
“The use of ultrafiltration provides medical providers an important solution to treat fluid overload patients in a variety of settings,” said John Erb, chairman and CEO of CHF Solutions. “We are pleased to have Dr. Beckles join us for this breakfast symposium to educate practitioners on clinical methodologies to optimize treatment outcomes in the post cardiovascular surgery setting.”
Interested participants can register for the symposium at http://www.chf-solutions.com/sts2019.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the company’s plans for the Society of Thoracic Surgeons Annual Meeting. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com